It revealed that OCT4, POU5F1B and BMI1P1 expression could serve as valuable biomarkers for distinguishing between AML and control subjects (AUC = 0.747, 95% CI: 0.627–0.867, P<0.001; AUC = 0.735, 95% CI: 0.587–0.883, P<0.01; AUC = 0.783, 95% CI: 0.624–0.941, P<0.001). This evidence concerns the gene POU5F1 and acute myeloid leukemia.